Table 4.

Studies on the use of FDG PET in localised bone sarcoma including outcome correlation and SUV thresholds

Reference	Year	Median age (years)	No. of patients	Histology	SUV1 (median)	End-point	SUV threshold	Survival (%)	p value
[7]	2005	18.7	36a	Ewing sarcoma	7.9	4-year PFS	<6	62	0.47
							≥6	52
[31]	2009	15	40b	Osteosarcoma	6.8	4-year PFS	>6	73	0.41
							≤6	63
[15]	2002	13.3	18	Osteosarcoma	8.2	ND
			15	Ewing sarcoma	5.3	ND
[22]	2009	14	70	Osteosarcoma	8	ND
[20]	2013	21	26	Osteosarcoma	9.2	ND
[16]	2002	14	26	Osteosarcoma	12.6	3-year EFS	12.6	90 28	<0.005
[25]	1996	19	4	Osteosarcoma	5.8	ND
		16	1	Ewing sarcoma	5.8
[19]	2006	17.5	10	Osteosarcoma	9.1	ND
[32]	2016	12.6	50	Ewing sarcoma	5	ND
Palmerini et al.	this study	17	32	Osteosarcoma	7.8	3-year EFS	<6	66	0.1
							≥6	32
		16	45	Ewing sarcoma	5.6	3-year EFS	<6	75	0.004
							≥6	37

EFS Event-free survival, PFS Progression-free survival, ND not done

^a12 metastatic

^b6 metastatic